E-Destek Kütüphanesi


Epi proColon® 2.0 CE Yayınları

Yıl Alıntı
2019 Roth et al. (American Health and Drug Benefits) Clinical and budget impact of increasing colorectal cancer screening by blood- and stool-based testing.
2019 Hitchins et al. (Open Gastro ) Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome.
2019 Potter et al. (CAP Today) FDA-approved DNA blood test for colorectal cancer prompts patient to undergo colonoscopy.
2018 Tierling et al. (Genetics and Epigenomics) Comprehensive Evaluation of Commercial Bisulfite-Based DNA Methylation Kits and Development of an Alternative Protocol With Improved Conversion Performance
2018 Bhangu et al. (Annals of Surgery) Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis.
2018 LeMieux (Clinical Omics) Eyeing Epigenetic Markers Identifying the Methylation Patterns of cfDNA Aids in Identifying Cancer’s Origin.
2018 Cai et al. (Journal of Clinical Epigenetics) Epi proColon®: Use of a Non-Invasive SEPT9 Gene Methylation Blood Test for Colorectal Cancer Screening: A National Laboratory Experience.
2017 de Vos et al. (Journal of Clinical Epigenetics) Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA.
2017 Song et al. (Scientific Reports): The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis
2017 Lamb et al. (Mol Diagn Ther.): Epi proColon® CE: A Blood-Based Screening Test for Colorectal Cancer
2017 Nian et al. (Clin Transl Gastroenterol.): Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis
2017 Song et al. (J Cancer Res Clin Oncol): The performance of the mSEPT9 assay is influenced by algorithm,
cancer stage and age, but not sex and cancer location
2016 Li et al. (Plos One): Diagnostic performance of DNA hypermethylation markers in peripheral blood for the detection of colorectal cancer: a meta-analysis an systematic review
2016 Wu et al. (J Mol Diagn ): Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening
2016 Toth et al. (Pathol. Oncol. Res.): Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients
2016 Song and Li (World J Gastrointest Oncol): Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests
2015 Orntoft et al. (BMC Cancer ): Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study
2014 Ladabaum et al. (Endoscopy International Open): Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA
2014 Toth et al. (PLoS One): Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA.
2014 Li et al. (Biomarkers Med. ): Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future
2014 Jin et al. (, J. Gastroenterol. Hepatol.): Performance of a second generation methylated SEPT9 test in detecting colorectal neoplasm
2014 Molnar et al. (Expert Rev. Mol. Diagn.): Plasma methylated septin 9: a colorectal cancer screening marker
2014 Adler et al. ( BMC Gastroenterology): Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany
2014 deVos (Clinical Laboratory International ): Blood-based tests for colorectal cancer screening
2013 Wasserkort et al. (BMC Cancer): Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island
2013 Ladabaum et al. (Cancer Epidemiology, Biomarkers & Prevention): Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated Septin9 DNA vs. current strategies
2012 Lofton-Day C et al. (Practical Gastroenterology): Opportunities and limitations of blood-based CRC screening tests. 
2012 Toth et al. (PLOS One): Detection of Methylated SEPT9 in Plasma Is a Reliable Screening Method for Both Left- and Right-Sided Colon Cancers
2011 Toth et al. (Pathology and Oncology Research): The Influence of Methylated Septin 9 Gene on RNA and Protein Level in Colorectal Cancer.
2010 Payne S et al. (Epigenomics): From discovery to the clinic: the novel DNA methylation biomarker mSEPT9 for the detection of colorectal cancer in blood.
2010 Tanzer et al. (PLOS ONE): Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions 
2010 Weiss and Rösch (European Oncology): Potential of a New Blood Test for Colorectal Cancer Screening – The Septin 9 Gene Biomarker
2009 deVos T et al. (Clinical Chemistry): Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
2008 Lofton-Day C et al. (Clinical Chemistry): DNA methylation biomarkers for blood-based colorectal cancer screening.
2008 Grützmann et al. (PLoS One): Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin9 DNA Methylation Assay